Navigation Links
AbbVie Declares Dividend and Announces Share Repurchase Program

NORTH CHICAGO, Ill., Feb. 15, 2013 /PRNewswire/ -- The board of directors of AbbVie Inc. (NYSE: ABBV) declared a quarterly cash dividend and also authorized a share repurchase program of up to $1.5 billion of the Company's outstanding common stock.

The cash dividend of $0.40 per share is payable May 15, 2013 to stockholders of record at the close of business on April 15, 2013.  AbbVie was named to the S&P 500 Dividend Aristocrats Index, which tracks companies that have annually increased their dividend for at least 25 consecutive years.  AbbVie was included as a result of the Index's change in its treatment of spin-off companies.

The share repurchase authorization, which is effective immediately, is expected to be completed over a multi-year period and purchases may be made from time to time in management's discretion. The share repurchase authorization permits shares to be repurchased in open market or private transactions, has no time limit and may be discontinued at any time.

About AbbVie

AbbVie is a global, research-based biopharmaceutical company formed in 2013 following separation from Abbott. With its 125-year history, the company's mission is to use its expertise, dedicated people and unique approach to innovation to develop and market advanced therapies that address some of the world's most complex and serious diseases. In 2013, AbbVie employs approximately 21,000 people worldwide and markets medicines in more than 170 countries. For further information on the company and its people, portfolio and commitments, please visit Follow @abbvie on Twitter or view careers on our Facebook or LinkedIn page.

Forward-Looking Statements

Some statements in this news release may be forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements.  Economic, competitive, governmental, technological and other factors that may affect AbbVie's operations are discussed in the "Risk Factors" section of the Information Statement attached to our Form 10 Registration Statement, which has been filed with the SEC, and are incorporated by reference.  AbbVie undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.

SOURCE AbbVie Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. BioMed Realty Trust Declares Fourth Quarter 2011 Common Stock and Preferred Stock Dividends
2. BioMed Realty Trust Declares Second Quarter 2012 Common Stock And Preferred Stock Dividends
3. Techne Corporation Declares Dividend
4. Techne Corporation Declares Dividend And Announces An Increase In Its Share Repurchase Program
5. Sigma-Aldrich Corporation Declares Increased Quarterly Dividend; Announces Live Webcasts Of Presentations At Two Upcoming Conferences
6. PDL BioPharma Completes Regular Quarterly Dividend Payment
7. Amgen Announces 2012 First Quarter Dividend
8. Osteologix Announces Dividend
9. Amgen Announces 2012 Third Quarter Dividend
10. CryoLife Announces Quarterly Cash Dividend for the Fourth Quarter 2012
11. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
Post Your Comments:
(Date:10/13/2015)... ... October 13, 2015 , ... InSphero AG , ... 3D cell culture models, has launched a 14 Day Hepatotoxicity Testing Service ... InSight™ Human Liver Microtissues. The service streamlines toxicity testing of compounds in ...
(Date:10/13/2015)... 2015 ARRY ), Avanex Life ... JUNO ), and Progenix Pharmaceuticals, Inc. (NASDAQ: PGNX ... Corp. (OTCQX: AVXLD), Juno Therapeutics, Inc. (NASDAQ: JUNO ... --> Cooperative research and development efforts with ... lead to advancements in the treatment of severe wounds. ...
(Date:10/13/2015)... , Oct. 13, 2015  According to ... services will reach $102 billion by the end ... of the health industry, as it is estimated ... result of laboratory tests. In addition to diagnosing ... to evaluate disease progression, monitor drug treatment and ...
(Date:10/13/2015)... ... October 13, 2015 , ... Proove Biosciences, a ... their partnership with the Keck Medicine of the University of Southern California ... T.R.O.J.A.N. Study (Therapeutic Evaluation to Research Clinical Objectives Linking Genotypic and Phenotypic Association ...
Breaking Biology Technology:
(Date:10/6/2015)... Calif. , Oct. 6, 2015  Maverix ... today announced enhancements to its software portfolio with ... analysis kit for differential expression in eukaryotes. The ... which is a cloud-based genomic analysis solution that ... scientific discovery from next-generation sequencing efforts. ...
(Date:10/2/2015)... -- ) has announced ... Using Biometrics" report to their offering. ... of the "Enforcing the Law Using Biometrics" ... Research and Markets ( ) has announced ... Using Biometrics" report to their offering. ...
(Date:9/30/2015)... -- With nearly 300,000 Americans living with spinal cord injuries ... reach 12,500 annually, the role of Independent Living Centers ... Living (SCRS-IL) is increasingly important. SCRS-IL is one ... opening doors to independence for individuals with SCIs by ... technology services and education. "In serving people ...
Breaking Biology News(10 mins):